Anti-ASAHL antibody - C-terminal (ab174621)

Overview

  • Product name
    Anti-ASAHL antibody - C-terminal
    See all ASAHL primary antibodies
  • Description
    Rabbit polyclonal to ASAHL - C-terminal
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human ASAHL aa 330-359 (C terminal) conjugated to Keyhole Limpet Haemocyanin (KLH). The exact sequence is proprietary.
    Database link: Q02083

  • Positive control
    • HL-60 cell line lysate.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer
    Preservative: 0.09% Sodium azide
    Constituent: 99% PBS
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Purification notes
    ab174621 is purified through a protein A column, followed by peptide affinity purification.
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab174621 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 40 kDa.

Target

  • Function
    Degrades bioactive fatty acid amides to their corresponding acids, with the following preference: N-palmitoylethanolamine > N-myristoylethanolamine > N-lauroylethanolamine = N-stearoylethanolamine > N-arachidonoylethanolamine > N-oleoylethanolamine. Also exhibits weak hydrolytic activity against the ceramides N-lauroylsphingosine and N-palmitoylsphingosine.
  • Tissue specificity
    Expressed in numerous tissues, with highest levels in liver and kidney, followed by pancreas.
  • Sequence similarities
    Belongs to the acid ceramidase family.
  • Post-translational
    modifications
    N-glycosylated. Tunicamycin treatment causes a reduction in specific activity against N-palmitoylethanolamine.
    Autoproteolytic cleavage in the acidic lumen of the lysosome activates the enzyme.
  • Cellular localization
    Lysosome.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acid ceramidase like protein antibody
    • Acid ceramidase-like protein antibody
    • ASAH like protein antibody
    • ASAH-like protein antibody
    • N acylethanolamine acid amidase antibody
    • N acylethanolamine hydrolyzing acid amidase antibody
    • N acylsphingosine amidohydrolase (acid ceramidase) like antibody
    • N acylsphingosine amidohydrolase like antibody
    • N acylsphingosine amidohydrolase like protein antibody
    • N-acylethanolamine-hydrolyzing acid amidase subunit beta antibody
    • N-acylsphingosine amidohydrolase-like antibody
    • Naaa antibody
    • NAAA_HUMAN antibody
    • PLT antibody
    see all

Images

  • Anti-ASAHL antibody - C-terminal (ab174621) at 1/100 dilution + HL-60 cell line lysate at 35 µg

    Predicted band size: 40 kDa

References

ab174621 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab174621.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up